Financial Performance - The company achieved a revenue of RMB 18,675.4 million, representing a year-on-year growth of 9.6%, with non-COVID revenue increasing by 13.1%[10] - Gross profit increased by 12.1% year-on-year, while net profit rose by 10.5% to RMB 3,945.4 million[10] - The company's revenue for the fiscal year ended December 31, 2024, reached RMB 18,675.4 million, representing a year-on-year growth of 9.6%[19] - Gross profit increased by 12.1% year-on-year to RMB 7,650.8 million, with a gross margin of 41.0% for 2024[19] - Net profit for the year was RMB 3,945.4 million, reflecting a year-on-year increase of 10.5%[19] - The revenue from North America rose significantly to RMB 10,695.8 million, accounting for 57.3% of total revenue, compared to RMB 8,073.5 million or 47.4% in the previous year[60] - IND pre-service revenue grew by 30.7% to approximately RMB 7,062.2 million, representing 37.8% of total revenue for the year ended December 31, 2024[62] - Revenue from the top five customers decreased by 10.2% to approximately RMB 5,442.3 million, representing 29.1% of total revenue for the year ended December 31, 2024[63] - Revenue from the XDC segment increased significantly to RMB 3,944.0 million, representing 21.1% of total revenue, compared to RMB 1,906.1 million or 11.2% in the previous year[66] - Adjusted net profit for the year ended December 31, 2024, was RMB 5,396.9 million, up from RMB 4,950.4 million in 2023, reflecting a growth of 9.0%[109] - Adjusted net profit margin for 2024 was 28.9%, slightly down from 29.1% in 2023[109] - Basic adjusted earnings per share increased to RMB 1.17 in 2024 from RMB 1.13 in 2023, while diluted adjusted earnings per share rose to RMB 1.12 from RMB 1.06[109] Operational Highlights - The company added 151 integrated projects, bringing the total to 817, with late-stage clinical and non-COVID commercialization projects reaching 66 and 21, respectively[10] - The company successfully supported over 600 IND submissions during the reporting period, reducing the development time from DNA to IND for mAb projects to nine months[10] - The company completed 16 process performance qualification (PPQ) projects, achieving a PPQ success rate of over 98% for drug substance (DS) and drug product (DP) production[11] - The company has 194 ongoing ADC and other bioconjugate drug iCMC projects globally, enhancing its position in the ADC market[11] - The company has established partnerships with the top twenty global pharmaceutical companies and most large pharmaceutical companies in China, expanding its customer base[20] - The total value of uncompleted orders as of December 31, 2024, amounted to USD 18.5 billion, including USD 10.5 billion in service orders and USD 8.0 billion in potential milestone payment orders[19] - The company has successfully acquired 20 external projects during the reporting period, including 13 clinical late-stage and commercialization projects, laying a solid foundation for future revenue growth[17] Technology and Innovation - The company has advanced its proprietary WuXiBody™ platform, achieving over 50 collaborations in the development of bispecific antibodies[23] - The CRDMO platform has enabled the company to empower over 600 IND submissions, significantly reducing the development cycle from DNA to IND to just nine months[29] - The WuXia™ platform has delivered over 1,000 cell lines, supporting 150 integrated CMC projects annually, making it one of the largest platforms in the industry[30] - The WuXiUP™ platform has been applied in over 140 processes, achieving production capacities of 20 to 100 grams per liter and enabling over 10 IND approvals[32] - The WuXiUI™ platform has increased the yield of various recombinant proteins by 3 to 6 times while maintaining high product quality and significantly reducing production costs[33] - The company has developed a comprehensive technology for validating tumor-associated antigens (TAA), enabling clients to discover potential best-in-class antibody-drug conjugates (ADCs)[27] - The group has established integrated platforms targeting emerging therapeutic modalities, enhancing service offerings and driving continuous growth and innovation[40] Compliance and Quality - All three facilities in Ireland received GMP certification from the HPRA, successfully completing multiple 16,000-liter scale PPQ productions[11] - The company has completed over 1,500 GMP audits and approximately 200 EU quality authorizations since 2017, maintaining high compliance standards[11] - The company is committed to maintaining the highest compliance standards and efficient operations to contribute to the global healthcare industry[13] - The group received multiple awards for quality service and ESG practices, including the "CDMO Leadership Award" for seven consecutive years[54] Sustainability and ESG - The company has made significant progress in sustainability, receiving multiple recognitions and awards from renowned rating agencies, including inclusion in the Dow Jones Sustainability Index[14] - The group joined the Science Based Targets initiative (SBTi) and became a participant in the UN Global Compact, enhancing its ESG performance[45] Governance and Management - The company emphasizes the importance of corporate governance and strategic guidance from its board members, leveraging their diverse backgrounds in finance and biopharmaceuticals[120] - The management team is focused on expanding the company's capabilities in biopharmaceutical development and production, with a strong emphasis on innovation and technology[118] - The board's composition includes members with significant experience in investment and strategic management, which supports the company's growth objectives[121] - The company is committed to maintaining high standards of governance and oversight to ensure sustainable growth and shareholder value[123] Financial Management - The company has a comprehensive financial risk management policy outlined in the annual report, ensuring robust oversight of financial performance[140] - The company has established a robust risk management system to evaluate significant risks, including operational, financial, and regulatory risks, to ensure effective operations[157] - The company is diversifying its revenue and profit sources to reduce dependence on any single country or region, while closely monitoring external environmental changes[159] - The company faces interest rate risks related to fixed-rate bank borrowings and floating-rate deposits, and it is managing these risks through careful assessment and potential interest rate swap agreements[160] Employee and Talent Management - The total number of employees reached 12,575, including 4,383 researchers, with a key talent retention rate of approximately 95.8%[113] - The company has adopted various equity incentive plans to reward eligible participants for their contributions[114] - The company aims to attract and retain key talent through the Global Partner Share Award Plan, which was adopted on June 16, 2021[188] Shareholder Information - As of December 31, 2024, Dr. Li has a 14.44% equity stake in the company, holding 592,902,633 shares[168] - The total number of issued shares as of December 31, 2024, is 4,105,937,505 shares[169] - The total number of options available for issuance under the pre-IPO share option plan is 145,700,858 shares, which is approximately 3.55% of the total issued shares[177] - The total number of restricted shares granted during the reporting period amounted to 79,063,961 shares, with 19,806,418 shares vested and 18,155,376 shares unvested[185]
药明生物(02269) - 2024 - 年度财报